ArticleCurrent medicinal chemistry2026
Metformin Reverses Progesterone Resistance in Endometrial Cancer by Targeting the AMPK-FOXO1-CALB2 Pathway.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProgesterone therapy is standard for fertility-preserving endometrial cancer (ECC) patients, but primary and secondary resistance limit its efficacy. Metformin (MET) combined with progesterone shows promise, yet the synergistic mechanism remains unclear. MATERIALS AND
methodsIn vitro cellular studies and nude mouse xenograft models were used. Cell proliferation, migration, and apoptosis were assessed by CCK8, flow cytometry, Western blot, and immunofluorescence. RNA sequencing and cell transfection verified that Forkhead box protein O1(FOXO1) inhibits ECC cell proliferation by downregulating Calbindin2 (CALB2). Xenograft models confirmed FOXO1's inhibitory role.
resultsMET combined with Megestrol acetate (MPA) inhibited the proliferation of ECC cells and induced cell apoptosis, and its effect was stronger than that of a single drug. MET promoted FOXO1 nuclear localization. FOXO1 suppressed ECC cell proliferation and migration in vitro and in vivo. MET inhibited proliferation via FOXO1-dependent CALB2 downregulation. Both MET treatment and CALB2 knockdown caused mitochondrial Ca2+ overload, membrane potential depolarization, and apoptosis, effects that were reversed by FOXO1 knockdown or CALB2 overexpression. DISCUSSION: MET with MPA inhibits proliferation and induces apoptosis in MPA-sensitive and resistant ECC cells. MET facilitates FOXO1 nuclear localization via adenosine monophosphate-activated protein kinase (AMPK) activation and AKT serine/threonine kinase 1 (Akt) inhibition. CALB2 is a key downstream target of nuclear FOXO1. The AMPK-FOXO1-CALB2 axis may represent a novel pathway activated by MET, inhibiting ECC proliferation and MPA resistance.
conclusionThe AMPK-FOXO1-CALB2 axis mediates MET-induced mitochondrial dysfunction and apoptosis, providing a mechanistic basis for MET to overcome progesterone resistance in ECC.
Indexed as
Identifiers
42163698What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.